Helica Instruments at the 26th AGE Congress 2026: Advancing Minimally Invasive Gynaecological Care in Berlin

For Helica Instruments, attendance at the AGE Congress is not simply a box to tick on an events calendar. It represents a deliberate and strategic step in our mission to ensure that the right clinical tools reach the right hands — and that the specialists who could benefit most from our technology have the opportunity to see it in action. This year's congress in Berlin was a particularly meaningful one, offering the perfect environment to demonstrate the capabilities of the Helica Thermal Coagulator to an audience of senior gynaecological consultants and endoscopy specialists at the forefront of minimally invasive practice.

The Congress of the Working Group for Gynecological Endoscopy has long been regarded as one of the most significant forums for gynaecological endoscopy in the European medical calendar. Now in its 26th edition, the congress draws together an exceptional calibre of clinical expertise — from practising surgeons and consultants to academic researchers and healthcare innovators. This kind of environment is precisely where meaningful clinical conversations take place. Unlike broader healthcare trade shows, the AGE Congress is focused, specialty-specific, and attended by professionals who are actively shaping the future of minimally invasive gynaecological care. For a company like Helica Instruments, whose technology is specifically designed to support this area of practice, there is no more relevant or productive stage. Engaging directly with gynaecological consultants at an event of this nature allows us to move beyond brochures and data sheets. It gives us the opportunity to have substantive, evidence-based conversations about clinical challenges, patient outcomes, and how the Helica Thermal Coagulator can genuinely make a difference in the operating theatre.

At the heart of our presence in Berlin was the opportunity to demonstrate the Helica Thermal Coagulator to gynaecological consultants who are always seeking safer, more effective, and less invasive solutions for their patients. The Helica Thermal Coagulator uses helium gas-based thermal energy to treat tissue with a high degree of precision and control. Unlike traditional electrosurgical tools, Helica does not require direct contact with tissue and produces no electrical current through the patient — characteristics that are particularly well-suited to sensitive gynaecological procedures. Its ability to coagulate effectively while minimising collateral thermal damage makes it a compelling option for surgeons focused on patient safety and procedural efficiency. For the specialists we met with in Berlin, seeing the technology demonstrated in context — understanding its practical application, its ease of integration into existing workflows, and the clinical evidence behind it — made for genuinely productive engagement. These are not passive conversations. They are the kind of exchanges that lead to informed purchasing decisions, meaningful clinical adoption, and ultimately, better outcomes for patients.

Our participation at the AGE Congress 2026 was made all the more impactful through our collaboration with Neomedic GmbH, our distributor partner in Germany. Strong distribution partnerships are not simply commercial arrangements — they are clinical relationships, built on shared values and a mutual commitment to serving the healthcare professionals and patients who depend on the products being represented. Neomedic GmbH brings deep market knowledge, established clinical relationships, and a respected presence within the German and broader European gynaecological community. Their support in Berlin ensured that the Helica Thermal Coagulator was presented with the context, credibility, and expertise it deserves. Together, we were able to engage with attendees at a level of depth and relevance that reflects the seriousness with which we approach every clinical market we enter. Partnerships like this one are central to Helica's European growth strategy. As we continue to expand access to the Helica Thermal Coagulator across the continent, working with distributors who understand local clinical environments — and who share our commitment to advancing minimally invasive care — is not just helpful. It is essential.

• Carl Dunn Whose leadership and deep product knowledge helped guide meaningful conversations with senior clinical professionals throughout the congress.
• Georg Schmidt Whose expertise and established relationships within the German gynaecological community were instrumental in opening doors and building confidence in the technology.
• Peter Brzoska Whose dedication and hands-on commitment to demonstrating the Helica system ensured that every interaction was informative, engaging, and clinically relevant.
• Antoni Castello Marcet Whose contributions to the team's overall effort and whose expertise in the field of gynaecological endoscopy added significant value to the discussions held throughout the event.

The conversations we had in Berlin are a reminder of why clinical engagement matters so profoundly. Behind every discussion about technology, there is a patient — a woman whose quality of care, recovery, and wellbeing may be shaped by the tools available to her surgeon. That is not a responsibility we take lightly. Helica Instruments' presence at events like the AGE Congress reflects a long-term commitment to being part of the clinical conversation — not just as a technology provider, but as a genuine partner to the professionals working at the forefront of minimally invasive gynaecological care. We believe that putting the right technology in front of the right people, supported by the right partnerships, is how meaningful clinical progress is made. The 26th AGE Congress in Berlin was a significant milestone in that journey. But as we said in Berlin — we are just getting started.